Literature DB >> 25835222

Computational analysis of drug transport in tumor microenvironment as a critical compartment for nanotherapeutic pharmacokinetics.

Arturas Ziemys1, Steve Klemm2, Miljan Milosevic3, Kenji Yokoi1, Mauro Ferrari1, Milos Kojic1,3,4.   

Abstract

Over the last decade, nanotherapeutics gained increasingly important role in drug delivery because of their frequently beneficial pharmacokinetics (PK) and lower toxicity when compared to classical systemic drug delivery. In view of therapeutic payload delivery, convective transport is crucial for systemic distribution via circulatory system, but the target domain is tissue outside vessels where transport is governed by diffusion. Here, we have computationally investigated the understudied interplay of physical transports to characterize PK of payload of nanotherapeutics. The analysis of human vasculature tree showed that convective transport is still 5 times more efficient than diffusion suggesting that circulating and payload releasing drug vectors can contribute mostly to systemic delivery. By comparing payload delivery using systemic circulation and drug vectors to microenvironment, internalized vectors were the most efficient and showed Area under the Curve almost 100 higher than in systemic delivery. The newly introduced zone of influence parameter indicated that vectors, especially internalized, lead to the largest tissue fraction covered with therapeutically significant payload concentration. The internalization to microenvironment minimizes effects of plasma domain on payload extravasation from nanotherapeutics. The computed results showed that classical PK, which mostly relies on concentration profiles in plasma, sometimes might be inadequate or not sufficient in explaining therapeutic efficacy of nanotherapeutics. These results provide a deeper look into PK of drug vectors and can help in the design of better drug delivery strategies.

Entities:  

Keywords:  Capillaries; diffusion; local concentration; pharmacokinetics; zone of influence

Mesh:

Year:  2015        PMID: 25835222      PMCID: PMC4673029          DOI: 10.3109/10717544.2015.1022837

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  21 in total

Review 1.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting.

Authors:  H Maeda
Journal:  Adv Enzyme Regul       Date:  2001

2.  Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics.

Authors:  Walter Wolf; Cary A Presant
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

Review 3.  Nanotherapeutics--product development along the "nanomaterial" discussion.

Authors:  Matthias G Wacker
Journal:  J Pharm Sci       Date:  2014-01-30       Impact factor: 3.534

4.  The role of pharmacokinetics in (combination) chemotherapy.

Authors:  J G McVie
Journal:  Cancer       Date:  1984-09-15       Impact factor: 6.860

5.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

Authors:  A N Gordon; J T Fleagle; D Guthrie; D E Parkin; M E Gore; A J Lacave
Journal:  J Clin Oncol       Date:  2001-07-15       Impact factor: 44.544

6.  A multiscale MD-FE model of diffusion in composite media with internal surface interaction based on numerical homogenization procedure.

Authors:  M Kojic; M Milosevic; N Kojic; K Kim; M Ferrari; A Ziemys
Journal:  Comput Methods Appl Mech Eng       Date:  2014-02-01       Impact factor: 6.756

7.  Extravascular diffusion in normal and neoplastic tissues.

Authors:  L J Nugent; R K Jain
Journal:  Cancer Res       Date:  1984-01       Impact factor: 12.701

8.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

Authors:  M E R O'Brien; N Wigler; M Inbar; R Rosso; E Grischke; A Santoro; R Catane; D G Kieback; P Tomczak; S P Ackland; F Orlandi; L Mellars; L Alland; C Tendler
Journal:  Ann Oncol       Date:  2004-03       Impact factor: 32.976

Review 9.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

Review 10.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

View more
  7 in total

1.  Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue.

Authors:  Aleksandra Karolak; Katarzyna A Rejniak
Journal:  Bull Math Biol       Date:  2018-02-08       Impact factor: 1.758

Review 2.  Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.

Authors:  Haifa Shen; Tong Sun; Hanh H Hoang; Jana S Burchfield; Gillian F Hamilton; Elizabeth A Mittendorf; Mauro Ferrari
Journal:  Semin Immunol       Date:  2017-09-23       Impact factor: 11.130

3.  Convection-Enhanced Delivery of Antiangiogenic Drugs and Liposomal Cytotoxic Drugs to Heterogeneous Brain Tumor for Combination Therapy.

Authors:  Ajay Bhandari; Kartikey Jaiswal; Anup Singh; Wenbo Zhan
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

4.  Liposomal doxorubicin extravasation controlled by phenotype-specific transport properties of tumor microenvironment and vascular barrier.

Authors:  Kenji Yokoi; Diana Chan; Milos Kojic; Miljan Milosevic; David Engler; Rise Matsunami; Tomonori Tanei; Yuki Saito; Mauro Ferrari; Arturas Ziemys
Journal:  J Control Release       Date:  2015-09-25       Impact factor: 9.776

5.  Capillary collagen as the physical transport barrier in drug delivery to tumor microenvironment.

Authors:  Arturas Ziemys; Kenji Yokoi; Milos Kojic
Journal:  Tissue Barriers       Date:  2015-05-06

6.  Progression-dependent transport heterogeneity of breast cancer liver metastases as a factor in therapeutic resistance.

Authors:  A Ziemys; K Yokoi; M Kai; Y T Liu; M Kojic; V Simic; M Milosevic; A Holder; M Ferrari
Journal:  J Control Release       Date:  2018-10-14       Impact factor: 9.776

7.  Targeting Ligand Specificity Linked to Tumor Tissue Topological Heterogeneity via Single-Cell Micro-Pharmacological Modeling.

Authors:  Aleksandra Karolak; Veronica C Estrella; Amanda S Huynh; Tingan Chen; Josef Vagner; David L Morse; Katarzyna A Rejniak
Journal:  Sci Rep       Date:  2018-02-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.